猪胆粉有效成分HDCA通过调控肠道胆汁酸代谢抑制胆固醇结石形成的实验研究
苏英洋 , 邓妍 , 刘星羽 , 杜玉珍 , 宁敏 , 吴姗 , 吴凯悦 , 沈双
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1016 -1026.
猪胆粉有效成分HDCA通过调控肠道胆汁酸代谢抑制胆固醇结石形成的实验研究
Experimental study on the inhibition of cholesterol gallstone forma- tion by HDCA, the active component of Pulvis Fellis Suis, through reg- ulation of intestinal bile acid metabolism
目的: 探究猪去氧胆酸(hyodeoxycholic acid,HDCA)通过调控肠道胆汁酸代谢,影响法尼醇 X 受体(farnesoid X receptor,FXR)活性,抑制胆固醇结石生成。方法: 将 C57BL/6J 小鼠随机分成对照组、胆固醇结石模型组、猪胆粉(pulvis fellis suis,PFS)(7%、10%)给药干预组,每组 6 只;将 C57BL/6J 小鼠随机分成对照组、胆固醇结石模型组、HDCA(0.1%、0.5%、1%)给药干预组,每组 6 只;对各组小鼠进行称重、拍照、收集各组织样本并进行胆囊结石等级评估;用总胆固醇(T-CHO)检测试剂盒和酶标仪检测样本中总胆固醇的含量;在体外细胞实验方面,通过实时定量聚合酶链反应 (qPCR)分析 HDCA 对肠道细胞中 FXR 的直接调节作用;使用 16S 核糖体 RNA(16S ribosomal RNA,16S rRNA)测序技术检测各组小鼠粪便菌群的变化差异;液相色谱-质谱法(liquid chromatography-mass spectrometry, LC-MS/MS)测定回肠组织中胆汁酸池的变化。结果: 与模型组相比,10%PFS 和 1%HDCA 给药干预组均显著降低小鼠胆囊胆固醇结石等级和血清胆固醇含量(P<0.01),并且 1%HDCA 组显著降低小鼠肝重与体质量的比值和肝脏胆固醇含量(P<0.01);在体外实验中,HDCA 显著降低肠道细胞 Caco-2 中 FXR 的相对表达量 (P<0.05、P<0.01);HDCA 显著降低疣微菌门(Verrucomicrobiota 与激活 FXR 型胆汁酸呈显著正相关)的含量(P<0.05),显著升高拟杆菌门(Bacteroidota 与激活 FXR 型胆汁酸呈显著负相关)的含量(P<0.01);并且 HDCA 显著改变肠道胆汁酸成分,降低激活 FXR 型胆汁酸含量占比,升高抑制 FXR 型胆汁酸含量占比(P<0.05)。结论: HDCA 可能通过调节肠道菌群提高抑制 FXR 型胆汁酸的含量,从而间接发挥抑制肠道 FXR,促进胆汁酸合成且降低胆固醇饱和度的作用,达到抑制胆固醇结石形成的效果。
AIM: To explore how hyodeoxycholic acid (HDCA) regulates intestinal bile acid metabolism and thereby modulates the activity of farnesoid X receptor (FXR) to inhibit the formation of cholesterol gallstones. METHODS: The C57BL/6J mice were randomly divided into a control group, a cholesterol gallstone model group, and a Pulvis fellis suis (PFS) (7%, 10%) administration intervention group (6 mice in each group). The C57BL/6J mice were also randomly divided into a control group, a cholesterol gallstone model group, and HDCA (0.1%, 0.5%, 1%) administration intervention groups (6 mice in each group). The mice in each group were weighed, photographed, and tissue samples were collected for gallstone grade assessment. The total cholesterol (T-CHO) content in the samples was detected using a total cholesterol detection kit and a microplate reader. In the in vitro cell experiments, the direct regulatory effect of HDCA on FXR in intestinal cells was analyzed by quantitative polymerase chain reaction (qPCR). The differences in fecal microbiota among the groups were detected using 16S ribosomal RNA (16S rRNA) sequencing technology. The changes in the bile acid pool in the ileum tissue were determined by liquid chromatography-mass spectrometry (LC-MS/MS). RESULTS: Compared with the model group, both the 10% PFS and 1% HDCA intervention groups significantly reduced the grade of cholesterol gallstones in the gallbladder and the serum cholesterol content of mice (P<0.01), and the 1% HDCA group significantly decreased the ratio of liver weight to body weight and the cholesterol content in the liver of mice (P<0.01); in the in vitro experiments, HDCA significantly reduced the relative expression level of FXR in intestinal cells Caco-2 (P<0.05,P<0.01); HDCA significantly reduced the content of theVerrucomicrobiota (which was significantly positively correlated with activated FXR-type bile acids) (P<0.05) and significantly increased the content of theBacteroidota (which was significantly negatively correlated with activated FXR-type bile acids) (P<0.01). Moreover, HDCA significantly changed the composition of intestinal bile acids, reducing the proportion of activated FXR-type bile acids and increasing the proportion of inhibitory FXR-type bile acids (P<0.05). CONCLUSION: HDCA may increase the inhibition of FXR-type bile acids by regulating the intestinal flora, thereby indirectly exerting the effect of inhibiting intestinal FXR, promoting bile acid synthesis and reducing cholesterol saturation, and achieving the goal of inhibiting the formation of cholesterol gallstones.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
刘乃辉, 张超良, 张成全, |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
汪静静, 彭景华, 刘毓, |
| [19] |
|
| [20] |
黄丹, 闫理姣, 万宛若, |
| [21] |
|
| [22] |
雷榆, 胡亚欣, 余蕾, |
| [23] |
|
| [24] |
李宛容, 陶梦婷, 邹元锋, |
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
Kumari A, Pathak DP, |
| [32] |
|
| [33] |
许趁意, 岳仁宋, 吕雪莲, |
| [34] |
Collins SL, Stine JC, Bisanz JE, |
| [35] |
|
| [36] |
段睿潇, 赵一帆, 叶永娟, |
| [37] |
|
国家自然科学基金项目(82200710)
上海健康医学院校院协同合作重点项目(XJJJ2503-6)
/
| 〈 |
|
〉 |